Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan

Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan

Abstract Background Carfilzomib is a selective proteasome inhibitor approved for treating relapsed or refractory multiple myeloma (RRMM). Carfilzomib improves overall survival (OS) and progression‐free survival (PFS); however, treatment with carfilzomib results in a higher incidence of cardiovascula...

Full description

Bibliographic Details
Main Authors: Hiromi Hagiwara, Takafumi Nakayama, Hiroya Hashimoto, Shigeru Kusumoto, Hidekatsu Fukuta, Takeshi Kamiya, Koichi Ikuta, Shinsuke Iida
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Cancer Medicine
Subjects:
carfilzomib
large claims database
lenalidomide
multiple myeloma
overall survival
renal impairment
Online Access:https://doi.org/10.1002/cam4.6457

Internet

https://doi.org/10.1002/cam4.6457

Similar Items